The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats

BACKGROUND: Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Karbownik, Agnieszka, Stachowiak, Anna, Urjasz, Hanna, Sobańska, Katarzyna, Szczecińska, Agnieszka, Grabowski, Tomasz, Stanisławiak-Rudowicz, Joanna, Wolc, Anna, Grześkowiak, Edmund, Szałek, Edyta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187206/
https://www.ncbi.nlm.nih.gov/pubmed/32016844
http://dx.doi.org/10.1007/s43440-019-00021-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187206/
https://www.ncbi.nlm.nih.gov/pubmed/32016844
http://dx.doi.org/10.1007/s43440-019-00021-0

Ejemplares similares